cudc-305

CUDC-305 is a novel orally active small molecule inhibitor of heat shock protein 90 (HSP90), belonging to the imidazopyridine class. HSP90 is a molecular chaperone that regulates the folding and stability of numerous client proteins involved in cell signaling, proliferation, and survival. By inhibiting HSP90α/β with high affinity (IC50 ~100 nM), CUDC-305 disrupts multiple oncogenic signaling pathways such as PI3K/AKT and RAF/MEK/ERK, leading to degradation of client proteins and induction of apoptosis in cancer cells. The drug demonstrates potent antiproliferative activity across a broad range of tumor types—including glioblastoma (with blood-brain barrier penetration), non-small cell lung cancer (including erlotinib-resistant lines), breast cancer, acute myelogenous leukemia—and has shown complete tumor regression in preclinical models. Additionally, it has been investigated for immune-mediated inflammatory skin diseases such as moderate-to-severe plaque psoriasis due to its ability to suppress proinflammatory gene expression[1][2][3][5][6].

Brand names

Debio 0932Debio0932Debio-0932

Other names

RGRN-305RGRN305RGRN 305Hsp90 inhibitor debio 0932Hsp-90 inhibitor debio 0932Hsp 90 inhibitor debio 0932